Yan Leyfman, Co-founder and executive director of MedNews Week, shared an article by Nirav N. Shah, et al. on LinkedIn:
“Dual-Targeted CAR T Therapy Shows 100% Response in Relapsed Mantle Cell Lymphoma (MCL).
A new phase I/II trial (NCT04186520) tested dual-targeted CD20/CD19 CAR T cells (LV20.19) in relapsed/refractory (R/R) MCL, showing promising efficacy and safety!
Key Findings:
- 100% overall response rate (88% complete response).
- Few relapses, with median follow-up of 15.8 months.
- Favourable safety: 94% had mild/moderate cytokine release syndrome, 18% had manageable neurotoxicity.
- Fast manufacturing: Most patients received CAR T cells within 8 days of apheresis.
This study highlights on-site adaptive CAR T manufacturing as a safe, efficient, and highly effective approach for MCL. Future research will determine long-term durability!
Click here for Manuscript.”
Phase I/II Study of Adaptive Manufactured Lentiviral Anti-CD20/Anti-CD19 Chimeric Antigen Receptor T Cells for Relapsed, Refractory Mantle Cell Lymphoma.
Authors: Nirav N. Shah, et al.
More posts featuring Yan Leyfman.